Navigation Links
Journal of Managed Care Pharmacy recognizes Prime Therapeutics with two 2012 JMCP Award for Excellence Honorable Mentions

ST. PAUL, Minn., May 7, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), announced today that it has been awarded two Honorable Mentions in the 2012 Award for Excellence from the Journal of Managed Care Pharmacy (JMCP).

One study examined the impact of generic drug discount programs on levothyroxine (a drug to treat low thyroid) pharmacy claims data. A second study reviewed members' medication use following the implementation of a rosiglitazone (a type 2 diabetes drug) safety prior authorization (PA) policy.

Pharmacies' Generic Drug Discount Programs - Potential Impact on PBM Claims Capture

Generic drug discount programs were popularized in 2006 when pharmacies such as Walmart began offering medications for as low as $4. While the programs reduce the cost of medicine for consumers, they may also reduce a PBM's ability to capture claims data, negatively impacting the ability to provide clinical programs and adherence reporting.

Prime compared claims from 3.5 million commercially insured members filling a levothyroxine prescription between January 1, 2006, and December 31, 2010. Researchers found an equivalent number of patients who did not continue a drug purchased at a non-membership pharmacy discount program, compared to a control group. On the other hand, those purchasing a generic through a membership program pharmacy appeared to have a small but statistically significantly higher rate of members who did not continue the drug.

"Although generic drug discount programs have been prevalent since 2008, it is a common concern that PBM and health plan prescription information is incomplete due to an unknown proportion of generic drug claims that are not submitted," said Patrick Gleason , PharmD, BCPS, FCCP and lead author and director of health outcomes for Prime. "These study results suggest that health insurers and PBMs should work to ensure that claims information is complete on pharmacies with membership drug discounts."

Authors of the study were: Alexandra Tungol , PharmD; Catherine I. Starner , PharmD, BCPS, CGP; Brent W. Gunderson , PharmD; Jeremy A. Schafer , PharmD, MBA; Yang Qiu , MS; and Gleason.

The study can be found at:

Rosiglitazone Prior Authorization Safety Policy

In the second study, Prime collaborated with Florida Blue to evaluate drug use among 1.4 million commercially insured members who were exposed to a rosiglitazone PA program beginning January 1, 2009. These members were compared with a group of approximately 2 million commercially insured members who did not have this safety PA intervention.

The study found that the rosiglitazone PA was successful in significantly reducing concurrent use of nitrates and insulin among health plan members with type 2 diabetes.

"Previous studies have found that prior authorization programs reduce drug utilization and costs, but it has been unclear whether patients were impacted positively or negatively," said Gleason. "Our study is unique in that the findings support the use of a PA to promote safe prescribing as evidenced by the potential cardiovascular event risk avoidance for patients."

The authors were: Catherine I. Starner , PharmD, BCPS,CGP; Beckie Fenrick , PharmD (formerly with Florida Blue ); Peter Wickersham , MS, MBA; and Patrick P. Gleason , PharmD, BCPS, FCCP (with Prime) and John Coleman , PharmD from Florida Blue .

The study can be found at:

The JMCP Award for Excellence entries are judged based on potential impact on the profession or knowledge, scientific merit and sound methodology, relevance to managed care pharmacy today, clarity of purpose and hypothesis, and writing quality and readability.

Prime received JMCP Award for Excellence honors in 2010 for its research examining the relationship between member out-of-pocket (OOP) costs and the number of patients who abandon high-cost specialty medications. In 2009, it was recognized for its research assessing rosiglitazone and pioglitazone utilization trends and associated medical and pharmacy claims data indicating risk for an adverse cardiovascular event.

Prime's 2012 Honorable Mention research studies will be recognized in a future issue of the AMCP Monthly News and posted on the AMCP/JMCP websites.

About Prime Therapeutics

Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves more than 21 million* people. It is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.

*Effective July 1, 2013.

SOURCE Prime Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
2. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
3. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
4. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
5. NAMS Journal Menopause Reflects on the WHI 10 Years Later
6. Elsevier and the Society for Vascular Surgery Announce Forthcoming Launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
7. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
8. MedVantx MedStart™ Solves Problem Highlighted in Study Published in Journal of the American Board of Family Medicine - Expired Medications in Physician Office Sample Closets
9. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
11. Medical Device Daily Wins Prestigious SIPA Award for Outstanding Business Journalism
Post Your Comments:
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
(Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... will provide scholarships for people struggling with eating disorders as a result of ... the second annual event, held at Fox Run Golf Club in Eureka, will ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a ... (TSC), as well as raising public awareness of the disorder while helping to ... third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
Breaking Medicine News(10 mins):